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Abstract
Members of the BMP and Wnt protein families play a relevant role in physiologic and pathologic bone turnover. Extracellular
antagonists are crucial for the modulation of their activity. Lack of expression of the BMP antagonist noggin by
osteoinductive, carcinoma-derived cell lines is a determinant of the osteoblast response induced by their bone metastases.
In contrast, osteolytic, carcinoma-derived cell lines express noggin constitutively. We hypothesized that cancer cell-derived
noggin may contribute to the pathogenesis of osteolytic bone metastasis of solid cancers by repressing bone formation.
Intra-osseous xenografts of PC-3 prostate cancer cells induced osteolytic lesions characterized not only by enhanced
osteoclast-mediated bone resorption, but also by decreased osteoblast-mediated bone formation. Therefore, in this model,
uncoupling of the bone remodeling process contributes to osteolysis. Bone formation was preserved in the osteolytic
lesions induced by noggin-silenced PC-3 cells, suggesting that cancer cell-derived noggin interferes with physiologic bone
coupling. Furthermore, intra-osseous tumor growth of noggin-silenced PC-3 cells was limited, most probably as a result of
the persisting osteoblast activity. This investigation provides new evidence for a model of osteolytic bone metastasis where
constitutive secretion of noggin by cancer cells mediates inhibition of bone formation, thereby preventing repair of
osteolytic lesions generated by an excess of osteoclast-mediated bone resorption. Therefore, noggin suppression may be a
novel strategy for the treatment of osteolytic bone metastases.
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Introduction
Skeletal metastasis is a common clinical manifestation in
advanced-stage patients suffering from prostate cancer (CaP)
[1,2] and mammary cancer (CaM) [3]. Bone metastases are the
most important cause of morbidity in these patients, with pain and
complications, including pathological fractures, spinal cord and
nerve compression requiring analgesia, irradiation and orthopedic
surgery, all associated with substantial costs [4].
At the metastatic site, tumor cells perturb the physiological bone
homeostasis controlled by osteoblasts and osteoclasts. CaM bone
metastases tend to elicit an osteolytic response, whereas CaP
metastases are prevalently associated with an osteosclerotic
reaction [5,6]. Both types of lesions compromise the skeletal
integrity and eventually lead to pathological fractures.
The exact mechanisms determining the osteolytic and osteo-
sclerotic lesions in bone metastases are not clearly defined yet. The
prevailing concept indicates that cancer cells secrete an excess of
paracrine factors stimulating directly or indirectly osteoclast or
osteoblast recruitment, thereby leading to unbalanced excess of
bone resorption or formation, respectively [7,8].
It is widely accepted that the osteolytic reaction in bone
metastasis results from an excess of osteoclast-mediated bone
resorption. Cancer cells release paradigmatic ‘‘osteolytic’’ cyto-
kines, such as parathyroid hormone-related protein (PTHrP),
receptor activator of NF-B ligand (RANKL), interleukin-8 (IL-8)
and colony stimulating factor-1 (CSF-1), directly or indirectly
responsible for the increase in osteoclast recruitment, activity and
survival. Subsequent release of growth factors from the bone
matrix fuels cancer cell growth, which in turn further stimulates
bone resorption, thus perpetuating the process and establishing a
‘‘vicious cycle’’ [5,9]. This hypothesis provides the rationale for
inhibition of bone resorption as therapeutic interference with
growth progression in osteolytic bone metastasis. However,
pharmacologic inhibition of bone resorption has only a minimal
or no positive impact on the healing of osteolytic lesions [10]. This
strongly suggests that, besides an increase in osteoclast-mediated
bone resorption, other mechanism(s) contribute to osteolysis.
The osteolytic lesion in multiple myeloma (MM) is not only the
result of an osteoclast-mediated increase in bone resorption [11],
but also of an uncoupling of the bone remodeling process
determined by a decrease in osteoblast-mediated bone formation
[12,13]. Several antagonists of the Wingless (Wnt) signaling
pathway, such as Dickkopf-1 (Dkk-1), secreted Frizzled-related
protein (sFRP) -1 and -2, are over-expressed by MM cells and may
contribute to the inhibition of Wnt-mediated osteoblast recruit-
ment and, therefore, to repression of bone formation [11,14,15].
This view is further corroborated by experimental evidence
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animal models of MM [16].
Previously, we have reported that the osteoinductive and
osteolytic potential in vivo of CaP and CaM cell lines can be
defined in vitro by their differential expression not only of osteolytic
cytokines, but also of the BMP antagonist noggin. Osteoinductive
cancer cell lines lack noggin expression, and the functional
relevance of this finding was emphasized by showing that noggin
forced expression in an osteoinductive CaP cell line abolishes the
osteoblast response induced by its bone metastases in vivo.
Conversely, constitutive noggin expression in vitro seems to be
the hallmark of osteolytic CaP and CaM cell lines [17]. We then
argued that, in analogy to what has been found for Dkk-1 in MM,
constitutive noggin release by osteolytic cancer cells might
contribute, through inhibition of bone formation, to the osteolytic
lesion in bone metastases of solid cancers.
To test this hypothesis, we first explored whether inhibition of
bone formationis a constituent of osteolytic lesionsinducedinbones
xenografted with the human CaP cell line PC-3. We then
investigated whether short hairpin RNA (shRNA)-mediated noggin
suppression in PC-3 cells, constitutively secreting this protein [17],
could preserve bone formation in the osteolytic lesions.
The osteolytic lesions in bones xenografted with PC-3 cells
showed morphological and histomorphometric parameters of
enhanced osteoclast-mediated bone resorption and decreased
osteoblast-mediated bone formation. In contrast, bones xenograft-
ed with noggin-silenced PC-3 cells were characterized by
structural and histological modifications indicative of bone
formation/repair activity. Therefore, noggin suppression in the
osteolytic cell line PC-3 seems to preserve the bone formation that
normally follows bone resorption, as an effect of the ‘‘coupling
phenomenon’’. Conversely, cancer cell-secreted noggin prevents
the repair of osteolytic lesions by uncoupling bone formation from
the osteoclast-mediated bone resorption, which is stimulated by
cancer cell-derived osteolytic cytokines.
Results
Silencing of Noggin mRNA and protein expression in the
PC-3/Fluc Cell clone by shRNA
The human osteolytic CaP cell line PC-3, constitutively
expressing the BMP antagonist noggin [17], was first transfected
with a luciferase-encoding vector to generate luc-positive clones. A
cell clone, PC-3/Fluc, was selected based on stable luc expression
and on gene expression profile in vitro, tumor take and bone
reaction after intra-osseous inoculation in vivo equivalent to those
of the parental PC-3 cells (Figure S1).
The PC-3/Fluc clone was subsequently transfected with a
combination of three different noggin-specific shRNA or with a
non-targeting shRNA to derive noggin knock-down (Nog-KD) and
negative control (mock) clones, respectively. Two Nog KD clones
(Nog-KD 14 and Nog-KD 17) were selected based on the
substantial reduction in noggin mRNA expression, as compared to
PC-3/Fluc cells (Figure 1A). Immunoblot analysis of noggin
protein secretion in the culture supernatant from the Nog-KD
clones 14 and 17 showed a reduction of 93% and 98%,
respectively (Figure 1B). Mock 5 clone showed an increase in
noggin mRNA expression. However, noggin protein expression in
this clone and in mock 4 was not affected.
Cell proliferation and expression of osteotropic factors of
the Noggin-silenced PC-3/Fluc cells in vitro
Cell proliferation in vitro of the mock and Nog-KD clones was
not affected, as compared to parental PC-3/Fluc (Figure 2A).
In order to verify whether noggin silencing would affect mRNA
expression of relevant osteotropic factors, the expression of Dkk-1,
PTHrP, RANKL, CSF-1 and IL-8 was also investigated
(Figure 2B). The expression of Dkk-1 and PTHrP was not
modified in all transfected clones, as compared to the PC-3/Fluc.
Consistently with previous investigations in parental PC-3 cells
[17], RANKL expression was undetectable in PC-3/Fluc, mock
and Nog-KD clones. CSF-1 was moderately up-regulated in all
mock and Nog-KD clones, although the elevation did not reach
significance. IL-8 expression was significantly higher in the mock
clones and, especially, in Nog-KD 17.
It has been shown in osteoblasts in vitro that expression of noggin
is BMP-dependent, indicating that a probable feedback mecha-
nism is necessary to maintain a BMP/noggin balance, thereby
limiting the BMP action on these cells [23]. A similar feedback has
also been reported in some prostate cancer-derived cell lines
[17,24]. The mRNA expression of BMP-2,-3,-6 and -7 was not
modified in both Nog-KD clones as compared to parental PC-3,
while BMP-4 mRNA was undetectable in both parental and Nog-
KD cells (not shown). Therefore, noggin silencing in PC-3 cells
does not alter either the level or the spectrum of their BMP
expression.
Effect on bone in vivo of Noggin-silenced PC-3/Fluc cells
A first experiment was terminated at day 25 after injection for
all groups of animals, while in a following experiment the
observation period for the Nog-KD clones was prolonged to 33
days. In both experiments the radiographic analysis detected the
onset of an equivalent osteolytic reaction in all groups of cancer
cell-bearing bones as early as day 14 after tumor cell xenografting
(not shown). At day 21 all xenografted tibiae still showed a similar
number and extension of osteolytic lesions, and an enlargement of
the bone shaft, as compared to sham-operated tibiae. However, in
Figure 1. Noggin silencing mediated by shRNA inhibits noggin
mRNA and protein expression. A. Noggin mRNA expression in PC-
3/Fluc cells, non targeting-vector-transfected clones (mock 4 and 5) and
Noggin-KD clones (Nog-KD 14 and 17). The mRNA expression levels (+/
2 SD) are quantified by real-time RT-PCR and normalized to b-actin as
endogenous control; mRNA level in PC-3/Fluc cells is set as 100%; the
mean of 2 to 3 independent experiments is shown. ***P,0.001, Nog-KD
clones versus PC-3/Fluc and mock clones. B. Noggin protein secreted in
the conditioned medium (CM) from PC-3/Fluc, mock and Nog-KD
clones. Equivalent amounts of proteins from concentrated CM were
immunoblotted with anti-noggin antibody. Equivalent protein loading
was verified by staining with Coomassie blue the total protein content
in the CM.
doi:10.1371/journal.pone.0016078.g001
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interposed between areas of osteolysis showed some evidence of
a more radio-dense aspect (Figure S2). In the first experiment,
both the radiography and the m-CT reconstruction performed at
the conclusion of the experiment (day 25) indicated further
development of predominantly osteolytic lesions in PC-3/Fluc- and
mock clone-bearing tibiae (Figure 3A and B). In contrast, in the
tibiae xenografted with the Nog-KD clones an evident increase in
radiodensity of the residual bone and, in addition, development of
bone spiculae projecting outside the cortex was invariably
observed (Figure 3A and B). In the second experiment the
observation period was prolonged in order to allow progression of
the bone response. The animals inoculated with the PC-3/Fluc
clone needed to be sacrificed at day 23 due to severe osteolysis of
the xenografted bones and swelling of the limb, and to signs of
pain and distress. In contrast, bones xenografted with the Nog-KD
clones showed a more preserved structural integrity and a less
pronounced swelling of the limb, with no signs of pain and distress.
Accordingly, the animals xenografted with Nog-KD 17 and Nog-
KD 14 clones were kept for a period of 30 and 33 days,
respectively. Consistently with the evolution of the bone response
observed in the first experiment, tibiae xenografted with Nog-KD
clones showed enhanced radiodensity of the residual bone and
pronounced bone spiculae projecting outside the cortex (Figure
S3A and B).
Modification of bone structural parameters induced in
vivo by Noggin-silenced PC-3/Fluc cells
Quantitative m-CT analysis confirmed that the tibiae xenograft-
ed with the PC-3/Fluc and mock clones had significantly lower
BV/TV ratio than the sham-operated ones. On the contrary, the
tibiae inoculated with the Nog-KD clones had higher BV/TV
ratio than with PC-3/Fluc and mock clones and were not different
from the sham-operated ones (Figure 4A).
Total bone mineral content measured by pQCT was lower in
the tibiae xenografted with the PC-3/Fluc and mock clones, as
compared with the sham-operated ones, but significance was
reached only for mock 5-xenografted bones. In contrast total bone
mineral content in the Nog-KD clones-xenografted tibiae was
higher than in PC-3/Fluc and mock clones-xenografted ones, but
reached significance only when compared to the mock clones
(Figure 4B).
Histomorphometry
In the tibiae xenografted with PC-3/Fluc and mock clones there
was a significant increase in osteoclast number and percentage of
surface covered by osteoclasts, as compared to the sham-operated
tibiae (Figure 5A and C). This was accompanied by a significant
decrease in osteoblast number and percentage of surface covered
by active osteoblasts (Figure 5B and D).
Tibiae xenografted with the Nog-KD clones showed signifi-
cantly lower number of osteoclasts and percentage of surface
covered by osteoclasts than those xenografted with PC-3/Fluc and
mock clones (Figure 5A and C). Conversely, they showed a
significantly higher number of active osteoblasts and percentage of
surface covered by osteoblasts than those inoculated with PC-3/
Fluc and mock clones. In Nog-KD clones-xenografted tibiae the
number of osteoblasts was higher than in the sham-operated
tibiae, but this increase was significant only for Nog-KD 14
(Figure 5B and D). Despite the fact that the mRNA expression of
IL-8, known to stimulate osteoclast recruitment, was significantly
up-regulated in vitro in the Nog-KD 17 clone, as compared to the
Nog-KD 14 clone, there was no obvious difference in the
osteoclast number between the bones xenografted with the two
Figure 2. Noggin silencing has no effect on cell proliferation
and affects only minimally the expression of osteotropic
factors, in vitro.A . In vitro proliferation of mock and Nog-KD clones
was measured by BrdU incorporation for 4 days and compared to PC-3/
Fluc cells. Average values of 3 independent experiments performed in
quadruplicate wells (+/2 SD). B. Expression of Dkk-1, PTHrP, RANKL,
CSF-1 and IL-8 mRNA. mRNA expression levels (+/2 SD) are quantified
by real-time RT-PCR and normalized to b-actin as endogenous control.
The mRNA expression level in PC-3/Fluc cells is set as 100%; the mean of
2 to 3 independent experiments is shown. ***P,0.001, mock and Nog-
KD 17 clones versus PC-3/Fluc and Nog-KD 14 clones.
doi:10.1371/journal.pone.0016078.g002
Figure 3. Noggin silencing promotes increase in radiodensity
and partial bone repair in advanced osteolytic lesions. A.
Representative images of radiography and B. 3-D reconstruction (m-CT)
of tibiae (top) and of 1 mm thick cross sections (bottom) of sham-
operated and cancer cell-xenografted tibiae at day 25 after intra-
osseous inoculation.
doi:10.1371/journal.pone.0016078.g003
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expression was functionally irrelevant.
Growth characteristics in vivo of Noggin-silenced
PC-3/Fluc cells
Tumor take was 100% for all xenografted clones. Weekly
monitoring and quantification of intra-osseous tumor growth by
BLI revealed that, in both experiments, noggin suppression in
cancer cells had a moderate impact on their proliferation in vivo.
Initially, the Nog-KD clones grew similarly to PC-3/Fluc and
mock clones. However, their growth progressively slowed down
and they could not reach the same tumor burden as for PC-3/Fluc
and mock clones (Figure 6). In the second experiment, where
tumor growth was monitored for longer periods, a growth arrest
was even observed (Figure S3C).
Metastatic potential of Noggin-silenced PC-3/Fluc cells
In order to investigate whether noggin silencing influences the
metastatic ability of PC-3 cells, systemic metastases were induced
by injection into the left cardiac ventricle.
The kinetics of development and the number of bone metastases
per mouse 28 days after intra-cardiac injection of Nog-KD 17 cells
did not differ from that induced by PC-3/Fluc and mock clones
(not shown). After intra-cardiac injection of PC-3/Fluc cells
systemic bone metastases develop asynchronously at variable bone
sites, making difficult a direct comparison of the radiographic
aspect and growth progression of metastatic lesions at the same
bone site among different animals. Furthermore, PC-3/Fluc cells,
like the parental PC-3, almost invariably metastasize to the jaw,
thereby impairing the nutritional status of the animals and,
consequently, limiting the length of the experimental observation.
These drawbacks prevented us to verify whether in this model the
bone response and the tumor growth induced by the Nog-KD
clone progress equally to those observed in the intra-osseous
model.
Discussion
Here we show for the first time that in the PC-3 xenograft
model of osteolytic bone metastasis the increase in osteoclast
number is associated with impairment in osteoblast number and
activity. This indicates that the osteolytic lesion is not only the
result of increased bone resorption, but also of an additional
Figure 4. Noggin silencing corrects the alterations of bone
structural parameters in osteolytic lesions. A. The ratio of bone
volume over total volume (BV/TV, +/2 SD) was determined by m-CT at
day 25 after tumor cells inoculation; n=6–7 animals for each
experimental group. ***P,0.001, mock 5 versus Nog-KD clones and
sham; **P,0.01, Nog-KD 14 versus PC-3/Fluc and mock 4; *P,0.05,
sham and Nog-KD 17 versus PC-3/Fluc and mock 4. B. Total bone
mineral content (TBMC; mg/mm +/2 SD) was measured by pQCT at day
25 after tumor cells inoculation; n=6–7 animals for each experimental
group. ***P,0.001, mock 5 versus Nog-KD 14; *P,0.05, sham and Nog-
KD 17 versus mock 5, and Nog-KD 14 versus mock 4.
doi:10.1371/journal.pone.0016078.g004
Figure 5. Noggin silencing normalizes the bone histomorpho-
metric indexes of bone formation and resorption in osteolytic
lesions. A. Number of osteoclasts (N.Oc/BS; /mm, +/2 SD) on the
endosteal surface in trabecular and cortical bone of sham-operated
tibiae or on residual bone adjacent to cancer cells of tibiae xenografted
with PC-3/Fluc, mock and Nog-KD clones. n=6–7 animals for each
experimental group. ***P,0.001, PC-3/Fluc and mock clones versus
sham, and mock clones versus Nog-KD 17; **P,0.01, Nog-KD 17 versus
PC-3/Fluc, and Nog-KD 14 versus PC-3/Fluc and mock clones. B. Number
of osteoblasts (N.Ob/BS; /mm, +/2 SD) on the endosteal surface in
trabecular and cortical bone of sham-operated tibiae or on residual
bone adjacent to cancer cells of tibiae xenografted with PC-3/Fluc,
mock and Nog-KD clones. n=6–7 animals for each experimental group.
***P,0.001, PC-3/Fluc and mock clones versus Nog-KD clones, and
mock 4 versus sham; **P,0.01, sham versus PC-3/Fluc and mock 5;
*P,0.05, Nog-KD 14 versus sham. C. Percentage of endosteal surface in
cortical and trabecular bone occupied by osteoclasts (Oc.S/BS; %, +/2
SD) in sham-operated and cancer cell-xenografted tibiae. n=6–7
animals for each experimental group. ***P,0.001, mock clones versus
sham and Nog-KD clones, and PC-3/Fluc versus sham and Nog-KD 17;
**P,0.01, Nog-KD 14 versus PC-3/Fluc. D. Percentage of endosteal
surface in cortical and trabecular bone occupied by osteoblasts (Ob.S/
BS; %, +/2 SD) in sham-operated and cancer cell-xenografted tibiae.
n=6–7 animals for each experimental group. ***P,0.001, PC-3/Fluc and
mock clones versus sham and Nog-KD clones.
doi:10.1371/journal.pone.0016078.g005
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mediated suppression of the constitutive expression of the BMP
antagonist noggin in PC-3 cells, without interfering with the host
microenvironment–derived noggin, restores the osteoblast number
and bone formation in bone lesions induced by these cells.
Accordingly, the bone response is converted from a purely
osteolytic to a mixed osteoblastic/osteolytic one. Collectively,
these results provide novel evidence strongly suggesting that
noggin secretion by CaP cells mediates the inhibition of the
osteoblast recruitment/activity. The resulting inhibition of bone
formation prevents the repair of the osteolytic lesion generated by
cytokine-stimulated, osteoclast-mediated bone resorption. Consis-
tently with this notion, noggin may represent a potential
therapeutic target in osteolytic CaP bone metastasis.
The molecular mechanisms governing the osteoblastic and the
osteolytic response in bone metastases by solid cancers are subject
of intensive investigation. In the osteolytic response, the attention
has been predominantly focused on extracellular factors and
signaling pathways that mediate the crosstalk between tumor cells
and the bone microenvironment leading to the vicious cycle of
tumor proliferation and bone resorption [25]. This hypothesis
postulates that factors such as PTHrP [26], RANKL [27] and IL-8
[28] are secreted by cancer cells and stimulate osteoclast
recruitment and activity. The consequent increase in bone
resorption releases matrix-embedded growth factors, such as
insulin-like growth factor (IGF) and transforming growth factor
beta (TGF-b), which, in turn, promote further cancer cell growth.
The influence of cancer cells on osteoblast recruitment and
activity has been studied almost exclusively in MM. Paradigmatic
molecules inducing directly osteoblast recruitment and, conse-
quently, bone formation, are members of the BMP and Wnt
protein families. Extracellular antagonists are crucial for the
modulation of their activities [29]. In a seminal study it has been
demonstrated that in MM secretion of the Wnt antagonist Dkk-1
by the neoplastic cells inhibits osteoblast recruitment and activity.
Accordingly, the osteolytic lesion in MM is not only the result of
increased bone resorption, but also of repressed bone formation
[30]. Furthermore, down-regulation of Dkk-1 expression seems to
mediate the osteoinductive activity of endothelin-1 (ET-1) [31].
Another extracellular antagonist of the Wnt pathway, sFRP-2,
may also contribute to this mechanism of inhibition of bone
formation [32].
The modulation of the osteoblast recruitment/activity and the
possible contribution of inhibition of bone formation in osteolytic
bone metastasis by solid cancers have received little attention. A
limited number of quantitative histomorphometric studies in
osteolytic metastases by a variety of epithelial cancers have shown
that, besides the increase in bone resorption, there is also
impairment in bone formation, especially in advanced lesions
[33,34,35]. It has been suggested that in these lesions bone
resorption is uncoupled from the subsequent bone formation
phase, which usually follows in normal bone remodeling [36]. This
phenomenon may be mediated by a direct, negative influence of
cancer cells on osteoblast recruitment, survival and activity, as
shown in vitro for osteolytic CaM and CaP cell lines [37,38,39].
The present investigation, showing that indexes of bone formation
are impaired in tibiae xenografted with PC-3 cells, further
supports the clinical findings above and strongly suggests that a
mechanism of uncoupling bone formation from resorption is also
operating in this model. However, the identity of the molecules
mediating this inhibitory effect on osteoblasts is yet unknown.
Antagonism of BMP activity by noggin is critical for embryonic
chondro-osteogenesis and joint formation [40]. Osteoblast-target-
ed over-expression of noggin results in osteopenia as the result of
impaired osteoblast recruitment [41,42], indicating that the
extracellular modulation of the BMP concentration is also essential
in adult life for the control of bone formation during bone
remodeling. BMPs and noggin reciprocally induce their expression
in osteoblasts [23], indicating that a positive feedback is necessary
for maintaining an optimal balance between BMP and noggin
concentrations in the bone microenvironment. Bone metastatic
cancer cells may interfere with this balance by secreting an excess
of either BMPs or noggin. It has been reported that BMP-6
expression positively correlates with CaP progression [43,44] and
that BMP-6 is the BMP primarily responsible for inducing an
osteoblast response in mouse models of CaP bone metastasis
[17,45]. However, in one of these reports we demonstrated that, in
addition, osteoinductive cancer cells lack secretion of the BMP
inhibitor noggin and that noggin forced expression in these cells
abolishes their osteoinductive activity in vivo. Therefore, an
unopposed effect of an excess of BMP-6 locally released by cancer
cells is also a determinant of the osteoblast response both in CaP
and CaM bone metastasis [17]. Likewise, low expression of the
Wnt antagonist Dkk-1 seems to favor the Wnt-induced osteoblast
response in CaP bone metastasis [46]. These two studies proved
for the first time that in osteoblastic bone metastases the
physiological, tight balance between osteoinductive BMP-6 and/
or Wnt proteins and their antagonists is tilted toward the first and,
thus, favors an abnormal osteoblast response. In contrast,
osteolytic CaM cell lines express BMP-2 and -4, while the
osteolytic CaP cell line PC-3 expresses BMP-3 [17,47]. However,
both CaP and CaM osteolytic cell lines express low or no BMP-6
[17,45] and BMP-7 [48,49] and, most importantly, secrete
constitutively relative high amounts of noggin [17]. Thus, in
osteolytic bone metastases the balance between BMPs and noggin
seems to be altered in a direction opposite to that of osteoblastic
bone metastases. The present study proves that this noggin-tilted
balance is responsible for the suppression of bone formation and,
thus, prevents repair of the osteolytic lesion. Furthermore, the
demonstration that specific targeting of the cancer cell-derived
noggin preserves bone formation/repair strongly suggests noggin
as a major ‘‘un-coupling factor’’ in osteolytic bone metastasis and
Figure 6. Noggin silencing limits growth of PC-3/Fluc cells in
bone xenografts. Bioluminescent signal (photons +/2 SD) emitted
from the cancer cell-xenografted tibiae was quantified at day 7, 14, 21
and 25 after intra-osseous inoculation of tumor cells; n=6–7 animals for
each experimental group. ***P,0.001, Nog-KD clones versus PC-3/Fluc
at day 25; *P,0.05, Nog-KD 14 versus PC-3/Fluc at day 21.
doi:10.1371/journal.pone.0016078.g006
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pathological bone remodeling.
Here we clearly show that noggin silencing in osteolytic PC-3
cells, although not correcting the bone architecture, restores the
bone mass of the xenografted tibiae, as assessed by radiography, m-
CT and pQCT. This effect on the bone mass is the result of
normalization or even enhancement of bone formation, as
indicated by histomorphometric parameters of osteoblast number
and activity. Noggin silencing in PC-3 cells does not alter either
the level or the spectrum of their BMP expression. As a result, the
physiological BMP/noggin balance in bone could be tilted in favor
of first by an excess of cancer cell-derived BMPs, which may
explain the trend toward increase in bone formation observed in
bone xenografted with Nog-KD PC-3 cells.
The bone repair is evident in advanced bone lesions, suggesting
that a time interval is necessary to restore bone formation,
consistently with the temporal organization of the physiological
bone remodeling (bone coupling). A similar mechanism of
restoration of bone coupling has been proposed to explain the
reparative bone formation in bone metastasis by solid cancers as
an effect of anti-cancer therapy [33,36,50].
The positive effect of noggin silencing on bone formation
supports our original hypothesis and suggests noggin as one of the
essential cancer cell-derived inhibitors of the osteoblast recruit-
ment/activity contributing to the osteolytic lesions in CaP bone
metastases. We have chosen a CaP model of osteolytic bone
metastasis to be consistent with our previous study demonstrating
that, conversely, lack of noggin has a relevant role in the
osteoblastic response in CaP bone metastases [17]. However, a
predominantly osteolytic phenotype is observed only in a small
percentage of CaP bone metastases, while it represents the
majority of the CaM metastases [5,6]. Therefore, in order to
extend the relevance of noggin in cancer-mediated osteolysis, it
will be important to confirm the present findings in a CaM model
of osteolytic bone metastasis. Nevertheless, it has already been
shown that inhibition of Dkk-1 by neutralizing antibodies in MM
in vivo [51,52], or in CaM cells in vitro [53], or by shRNA-mediated
interference in CaP cells in vitro [54] is also able to restore bone
formation suppressed by neoplastic cells. Furthermore, Dkk-1
serum levels are elevated in CaM patients with bone metastases,
but not in CaM patients with soft tissue metastases, and it has been
suggested that Dkk-1-induced inhibition of bone formation may
contribute to the osteolytic lesion in CaM [55]. Collectively, these
and the present investigation support the view that cancer cell-
derived antagonists of both BMP and Wnt signaling pathways
contribute to the severity of the osteolytic process not only in MM,
but also in various types of epithelial cancer. The BMP and Wnt
signaling pathways clearly cooperate and regulate each other, but
the exact hierarchy of these two pathways in stimulating osteoblast
recruitment and activity is still debated [56,57,58,59].
In the late phase of the experimental observation, concomitantly
to bone repair, noggin silencing in cancer cells also reduces tumor
growth. The fact that the growth rate in vitro of noggin-silenced
clones is not affected suggests that this effect in vivo may be exerted
through an influence of the bone environment. Restoration of
bone formation may physically limit the intramedullary space
available for cancer cell expansion [60]. However, in this case
cancer cells would most probably invade the surrounding soft
tissue through trans-cortical, vascular channels, as it has been
observed when bone resorption is inhibited [61,62]. Most likely,
osteoblasts may secrete factors inhibiting tumor growth directly
[63]. One of these factors could be BMP-7, which we have
previously demonstrated to inhibit tumor growth in animal models
of osteolytic bone metastasis [48,49]. Osteolytic cancer cell-
derived noggin may antagonize endogenous, osteoblast-derived
BMP-7 and, therefore, allow escape from its inhibitory effect on
tumor growth. Alternatively, osteoblasts may affect tumor growth
indirectly, acting through an inhibition of osteoclast recruitment
[39,60]. The latter, indirect mechanism is also suggested by the
decreased osteoclast number and activity observed in tibiae
xenografted with noggin-silenced PC-3 cells. Taken together,
these observations indicate that restoration of bone formation may
limit growth progression in osteolytic bone metastasis.
The establishment of systemic bone metastases induced by
injection into the left cardiac ventricle of noggin-silenced PC-3
cells is not impaired. This suggests that interference with the
constitutive secretion of noggin by cancer cells does not affect the
early steps of the bone metastatic colonization (adhesion and
extra-vasation) and, especially, the growth initiation by the
osteolytic process.
It has been previously reported that exogenous noggin inhibits
BMP-2- and BMP-4-induced invasion and migration of PC-3 cells,
in vitro, and that noggin over-expression in the same cells limits
their expansion and osteolytic activity, in vivo [64]. This finding is
apparently in contradiction with our present study, showing that
noggin silencing, rather than over-expression, limits tumor growth
and osteolysis in the same PC-3 bone xenograft model. Most likely,
noggin over-expression in PC-3 cells antagonizes the overall BMPs
secreted by both cancer cells and the bone microenvironment and,
accordingly, interferes not only with their direct, stimulatory effect
on the invasive capacity of PC-3 cells, but also with their normal,
stimulatory role in bone formation. In contrast, noggin silencing in
PC-3 cells targets exclusively the noggin of cancer cell origin,
thereby eliminating its interference with the physiological BMP/
noggin balance within the bone microenvironment. Accordingly,
noggin silencing seems to be a more targeted mean to understand
the role of noggin in osteolytic bone metastasis.
Based on the present results we postulate a revised model for the
pathogenesis of osteolytic bone metastasis by solid cancers, where
the osteolytic lesion is not only the result of excess of bone
resorption induced by cancer cell-derived factors stimulating
osteoclast recruitment and activity, but also of uncoupling bone
formation through noggin constitutively secreted by cancer cells.
Conversely, suppression of cancer cell-derived noggin restores the
bone formation phase, which is physiologically coupled to the
initial phase of bone resorption. As a result of this anabolic effect,
tumor progression is contained by yet unidentified, osteoblast-
derived factors (Figure 7). Thus therapeutic neutralization of
noggin may not only favor bone repair, but also control bone
metastatic growth.
Targeting of the RANK/RANKL axis has been proven to
successfully inhibit osteolysis in numerous animal models of bone
metastasis [65] and this evidence has contributed significantly to
the strategy to develop a humanized monoclonal antibody against
RANKL for treating osteolytic bone disease [66]. The evidence
presented in this investigation, suggesting that a dual mechanism
of stimulated bone resorption and inhibited bone formation is
responsible also for the osteolytic lesion by solid cancers, provides
the rationale for a combinatorial targeting of both, the RANK/
RANKL axis and the BMP antagonist noggin for a more effective
control of bone metastatic growth.
Materials and Methods
Ethics statement
Experimental animal protocols, anesthesia, surgical procedure
and post-surgical analgesia were approved by the Committee for
Animal Experimentation and the Veterinary Authorities of the
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individual ventilated cages in strict accordance to the Swiss
Guidelines for the Care and Use of Laboratory Animals.
Autoclaved water and sterile mouse chow were provided ad
libitum. Animals xenografted with human cancer cells were
carefully monitored for signs of pain or distress, loss of body
weight and radiological signs of severe osteolysis and imminent risk
fracture. When any of these signs appeared or at the end of the
experimental period, the mice were sacrificed by CO2 euthanasia.
Animals
BALB/c nude mice were purchased from Charles River France
(L’Arbresle, France) and they were 7-8 weeks old when used for
the intra-osseous inoculation of tumor cells and 5 weeks old for the
intra-cardiac injection. For surgical manipulation, mice were
anesthetized as described previously [18].
Cell lines and cell culture
The osteolytic human CaP cell line PC-3 (ATCC/LGC
Promochem, Molsheim, France) was grown in Dulbecco’s
modified Eagle’s medium supplemented with 10% FBS (Biochrom
AG, Berlin, Germany) and antibiotics. Cells were shown to be free
of mycoplasma by PCR (Venor GeM, Minerva Biolabs GmbH,
Berlin, Germany).
PC-3 cell-derived clones
For in vivo tracking, PC-3 cells were permanently transduced with
thefireflyluciferase(Fluc) usinga self-inactivating lentiviralvector [19]
and cloned by limiting dilution. The PC-3/Fluc clone was
electroporated (Nucleofector, Amaxa, Lonza, Verviers, Belgium)
with either the combination of three vectors containing shRNA
targeting the noggin transcript or a non-targeting sequence
(SureSilencing, SABiosciences, LucernaChem, Lucerne, Switzerland)
to generate Noggin knock-down (Nog-KD) and negative control
(mock) clones, respectively. The sequences of the shRNA used are
listed in Supporting Information (Table S1). Individual stably
transfected clones were derived by selection with Puromycin (1 ug/
ml) and Neomycin (200 ug/ml) (Sigma-Aldrich, Buchs, Switzerland).
Generation of conditioned media
Cells were seeded at a density of 2.5610
4 cells/cm
2 in 10 cm
culture dishes. After 1 day, the medium was replaced with 10 ml
serum-free medium and the cells were cultured for further
48 hours. The cell-conditioned media (CM) were centrifuged
and stored at –20uC for later use. The cell number was determined
and the volume of CM was adjusted for differences in cell density
between samples. CM were dialyzed against serum-free medium
and concentrated 10-fold by lyophilisation.
Cell proliferation assay
Cells were seeded at a density of 10
4 cells/cm
2 in microtiter
plates and cultured for 4 days. Cell proliferation was determined
by measuring bromodeoxyuridine (BrdU) incorporation with a
colorimetric ELISA (Cell Proliferation ELISA, BrdU; Roche
Diagnostics, Rotkreuz, Switzerland) according to the manufactur-
er’s protocol.
Figure 7. Model of osteolysis integrating a dual mechanism of stimulated bone resorption and ‘‘uncoupled’’ bone formation. The
osteolytic lesion is the net result of two different mechanisms leading to uncoupling of normal bone remodeling: A. Excess of bone resorption,
consequent to enhanced osteoclast recruitment and activity induced by cancer cell-derived osteolytic cytokines. The subsequent release of bone
matrix-integrated growth factors further stimulates cancer cell growth. B. Suppression of bone formation, consequent to interference with osteoblast
recruitment and activity induced by cancer cell-derived noggin. C. Noggin silencing in cancer cells re-establishes osteoblast recruitment and activity,
and, thus, ‘‘bone coupling’’, with consequent bone formation/repair. As an effect of the rescued osteoblast activity, tumor progression is contained
by yet unidentified osteoblast-derived factors.
doi:10.1371/journal.pone.0016078.g007
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Total RNA extraction from subconfluent cultures of PC-3/Fluc
cells and the various clones was performed with RNeasy (Qiagen,
Hombrechtikon, Switzerland). Reverse transcription was per-
formed with M-MLV-RT (Promega, Wallisellen, Switzerland) and
random primers (Roche Diagnostics). Human-specific real-time
PCR primers and probes (Applied Biosystems, Rotkreuz, Switzer-
land) are listed in Supporting Information (Table S2).
Immunoblotting
Noggin secretion by PC-3/Fluc cells and by the different clones
was determined in concentrated CM, normalized by the total cell
number collected from each sample. Proteins were separated on
12% sodium dodecyl sulfate-polyacrylamide gels (Mini Protean
Gel BioRad) and transferred on Hybond-P membranes (GE
Healthcare, Glattburg, Switzerland). Membranes were incubated
overnight with 40 ng/ml of a rat monoclonal antibody against the
human native noggin protein [20] (RP57-16; kindly provided by
Dr. A.N. Economides, Regeneron Pharmaceuticals, Inc.) and
detected with a horseradish peroxidase-labeled anti-rat secondary
antibody (1:1000; GE Healthcare). Immunoreactivity was visual-
ized with the ECL Advanced chemiluminescence substrate (GE
Healthcare) using the VersaDoc imaging system (Bio-Rad
Laboratories, Reinach, Switzerland) and signal intensity was
quantified with QuantityOne imaging software (Bio-Rad Labora-
tories). Equivalent protein loading was verified by staining with
Coomassie blue the total protein content in the CM.
Intra-osseous inoculation of PC-3/Fluc cells, mock and
Nog-KD clones
The cells were inoculated into the marrow cavity of the left tibia
at a concentration of 5610
5/10 ml of phosphate-buffered saline
(PBS), as previously described [18]. Groups of seven animals each
were inoculated with either PC-3/Fluc cells, mock or Nog-KD
clones. Another group of 7 animals, inoculated with phosphate-
buffered saline alone served as control (= sham). In a first
experiment tumor growth was allowed to progress until day 25, at
which time animals from all groups were sacrificed because of the
severe osteolysis and imminent risk of fracture in the PC-3/Fluc
and mock groups. In a further experiment the animals xenografted
with the PC-3/Fluc clone were sacrificed at day 23 for the same
reason above, while the groups xenografted with Nog-KD 14 and
17 clones were kept for a period of 30 and 33 days, respectively.
The xenografted and sham-operated tibiae were dissected and
fixed in 4% paraformaldehyde (PFA).
Intra-cardiac injection of PC-3/Fluc cells, mock and
Nog-KD clones
The cells were injected into the left cardiac ventricle at the
concentration of 10
5/100 ml in PBS, as previously described [18].
Groups of ten animals each were injected with either PC-3/Fluco r
mock 4 or Nog-KD 17 clones. Animals were sacrificed 28 days
after injection.
Radiography
Radiographs of the mice were taken weekly using a Faxitron
radiography system (MX-20, Faxitron X-Ray Corporation,
Edimex, Le Plessis, France) to monitor changes in bone structure
and radiodensity.
In vivo bioluminescent imaging (BLI)
Tumor growth was monitored non-invasively in the living
animals by bioluminescent imaging (BLI) at weekly intervals as
previously described [18] using an ultrasensitive charge-coupled
device (CCD) camera (NightOWL LB, Berthold Technologies,
Bad Wilbad, Germany). In vivo photon counts were normalized for
the in vitro luciferase activity by PC-3/Fluc clone, mock and Nog-
KD clones.
Three-dimensional micro-computer tomography (m-CT)
of bone lesions
To obtain qualitative and quantitative assessment of the tumor-
induced modifications of the bone structure, sham and tumor-
bearing tibiae were scanned ex vivo, at the end of the experimental
period, with a m-CT40 scanner (SCANCO Medical AG,
Bru ¨ttisellen, Switzerland) at a resolution of 6 mm. The region of
interest was selected from the scout view and 1600 micro-
tomographic slices were acquired, covering three quarters of the
length of the tibia. Tridimensional images were obtained through
reconstruction of cross sectional images. Quantitative analysis of
primary parameters such as total volume (TV) and bone volume
(BV) was performed on a volume of interest equivalent to 166
slides (1 mm in length) at approximately 2.5 mm distal from the
cleft of the knee joint as reference point.
Peripheral quantitative computed tomography (pQCT)
Bone mineral content in the xenografted tibiae was determined
ex vivo with a small animal pQCT scanner (XCT Research SA;
Norland Stratec, Pforzheim, Germany) at the end of the
experimental period. Measurements were performed at 2 and
3 mm distal from the reference point (cleft of the knee joint).
Bone histomorphometry
Fixed tibiae were decalcified in a solution of PFA 0.5%/EDTA
15% for 20 days and processed for paraffin embedding. Four-mm
sections were stained for tartrate-resistant acid phosphatase
(TRAP) as described previously [21], counterstained with
hematoxylin and examined by light microscopy. Osteoclasts were
counted as multinucleated TRAP-positive cells on the endosteal
surface of cortical and trabecular bone in sham-operated tibiae,
and on the residual bone adjacent to tumor cells in cancer cell-
xenografted tibiae. The number of osteoclasts (N.Oc/BS; /mm)
and of active osteoblasts (N.Ob/BS; /mm), the bone surface
covered by osteoclasts (Oc.S/BS; %) and osteoblasts (Ob.S/BS; %)
were determined using the OsteoMeasure histomorphometry
software (OsteoMetrics Inc., Decatur, GA, USA). Osteoclasts
and osteoblasts were counted in randomly selected fields of an area
.1m m
2, approximately at 1.5 mm from the growth plate. Bone
parameters were expressed as recommended in the report of the
ASBMR Histomorphometry nomenclature committee [22].
Statistical analysis
Graph Pad Prism version 4.00 for Windows (GraphPad
Software, San Diego, CA, USA) was used for all statistical
analyses. The parametric one-way ANOVA test with a Bonferroni
post-test was used to analyze the RNA expression data, the bone
architecture parameters obtained by m-CT and pQCT, and the
histomorphometric data. To compare the cell proliferation rate in
vitro and in vivo the parametric two-way ANOVA test was
employed. P values smaller than or equal to 0.05 were considered
as significant.
Supporting Information
Figure S1 Luciferase expression does not modify the
osteolytic potential of PC-3 cells and moderately affects
their gene expression in vitro.A . Representative images of
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PLoS ONE | www.plosone.org 8 January 2011 | Volume 6 | Issue 1 | e16078radiography of tibiae xenografted with PC-3 or PC-3/Fluc cells at
day 28 after intra-osseous inoculation. B. Expression of noggin,
Dkk-1, PTHrP, RANKL, CSF-1 and IL-8 mRNA. mRNA
expression levels (+/2 SD) are quantified by real-time RT-PCR
and normalized to b-actin as endogenous control. mRNA
expression level in PC-3 cells is set as 100%; the mean of 2 to 3
independent experiments is shown. ***P,0.001, PC-3/Fluc versus
PC-3 cells.
(TIF)
Figure S2 Noggin silencing promotes increase in radio-
density in advanced osteolytic lesions. Radiographic aspect
of sham-operated and cancer cell-xenografted tibiae at day 21
after intra-osseous inoculation.
(TIF)
Figure S3 Noggin silencing promotes partial bone
repair in advanced osteolytic lesions and limits late
tumor growth. A. Radiographic aspect and B. 3-D reconstruc-
tion (m-CT) of tibiae xenografted with PC-3/Fluc and Nog-KD
clones, at day 23 (PC-3/Fluc), day 30 (Nog-KD 17) and day 33
(Nog-KD 14) after inoculation. C. Growth in vivo of PC-3/Fluc and
Nog-KD clones. Bioluminescent signal (photon counts +/2 SD)
emitted from the cancer cell-xenografted tibiae was quantified at
day 7, 14, 21, 23, 28, 30 and 33 after intra-osseous implantation of
tumor cells; n = 6–7 animals for each experimental group.
***P,0.001, Nog-KD clones versus PC-3/Fluc at day 21.
(TIF)
Table S1 The sequence of the different shRNA obtained from
Superarray is shown.
(DOC)
Table S2 Assay ID of the real-time primers and probes obtained
from Applied Biosystems are listed.
(DOCX)
Acknowledgments
We would like to thank I. Klima, U. Gerber and A. Lozano for their
excellent technical assistance. A special thank to M. Siegrist, Bone Biology,
Department of Clinical Research, University of Bern, CH, for his help with
the m-CT measurements. We are grateful to the members of the Academic
Unit of Bone Biology, University of Sheffield, UK, for training CS in the
use of Osteomeasure. We also thank Dr. A. N. Economides, Regeneron
Pharmaceuticals, Inc, for the gift of anti-noggin antibodies. We are
indebted with Dr. W. Hofstetter, Bone Biology, Department of Clinical
Research, University of Bern, CH, for helpful discussions and criticism and
with Dr. M. Tschan, Medical Oncology and Hematology, Department of
Clinical Research, University of Bern, CH, for providing us with the
luciferase lentiviral vector.
Author Contributions
Conceived and designed the experiments: MGC AW CS. Performed the
experiments: CS MGC. Analyzed the data: CS AW RS MGC. Wrote the
paper: CS AW MGC. Revised the manuscript and approved the final
version: MGC GNT.
References
1. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, et al. (2000)
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum
Pathol 31: 578–583.
2. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, et al. (2003) Phenotypic
heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol
34: 646–653.
3. Kozlow W, Guise TA (2005) Breast cancer metastasis to bone: mechanisms of
osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 10:
169–180.
4. Lage MJ, Barber BL, Harrison DJ, Jun S (2008) The cost of treating skeletal-
related events in patients with prostate cancer. Am J Manag Care 14: 317–322.
5. Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:
1655–1664.
6. Mundy GR (1997) Mechanisms of bone metastasis. Cancer 80: 1546–1556.
7. Logothetis CJ, Lin SH (2005) Osteoblasts in prostate cancer metastasis to bone.
Nat Rev Cancer 5: 21–28.
8. Suva LJ, Griffin RJ, Makhoul I (2009) Mechanisms of bone metastases of breast
cancer. Endocr Relat Cancer 16: 703–713.
9. Chirgwin JM, Guise TA (2000) Molecular mechanisms of tumor-bone
interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 10: 159–178.
10. Mundy GR, Sterling JA (2008) Metastastic solid tumors to bone. In: Rosen CJ,
ed. Primer on the netabolic bone diseases and disorders of mineral metabolism.
7th ed. Washington DC: American Society for Bone and Mineral Research. pp
374–378.
11. Roodman GD (2010) Targeting the bone microenvironment in multiple
myeloma. J Bone Miner Metab.
12. Bataille R, Chappard D, Alexandre C, Dessauw P, Sany J (1986) Importance of
quantitative histology of bone changes in monoclonal gammopathy. Br J Cancer
53: 805–810.
13. Taube T, Beneton MN, McCloskey EV, Rogers S, Greaves M, et al. (1992)
Abnormal bone remodelling in patients with myelomatosis and normal
biochemical indices of bone resorption. Eur J Haematol 49: 192–198.
14. Qiang YW, Barlogie B, Rudikoff S, Shaughnessy JD, Jr. (2008) Dkk1-induced
inhibition of Wnt signaling in osteoblast differentiation is an underlying
mechanism of bone loss in multiple myeloma. Bone 42: 669–680.
15. Qiang YW, Chen Y, Stephens O, Brown N, Chen B, et al. (2008) Myeloma-
derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL
production by osteoblasts: a potential mechanism underlying osteolytic bone
lesions in multiple myeloma. Blood 112: 196–207.
16. Heath DJ, Chantry AD, Buckle C, Coulton L, Shaughnessy JD, et al. (2008)
Inhibiting Dickkopf-1 (Dkk-1) prevents the development of osteolytic bone
disease in multiple myeloma. Calcified Tissue International 83: 6–6.
17. Schwaninger R, Rentsch CA, Wetterwald A, van der Horst G, van
Bezooijen RL, et al. (2007) Lack of noggin expression by cancer cells is a
determinant of the osteoblast response in bone metastases. Am J Pathol 170:
160–175.
18. Wetterwald A, van der Pluijm G, Que I, Sijmons B, Buijs J, et al. (2002) Optical
imaging of cancer metastasis to bone marrow: a mouse model of minimal
residual disease. Am J Pathol 160: 1143–1153.
19. Swan CH, Buhler B, Steinberger P, Tschan MP, Barbas CF, 3rd, et al. (2006) T-
cell protection and enrichment through lentiviral CCR5 intrabody gene
delivery. Gene Ther 13: 1480–1492.
20. Gazzerro E, Du Z, Devlin RD, Rydziel S, Priest L, et al. (2003) Noggin arrests
stromal cell differentiation in vitro. Bone 32: 111–119.
21. Sundquist KT, Cecchini MG, Marks SC, Jr. (1995) Colony-stimulating factor-1
injections improve but do not cure skeletal sclerosis in osteopetrotic (op) mice.
Bone 16: 39.
22. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, et al. (1987)
Bone Histomorphometry - Standardization of Nomenclature, Symbols, and
Units. Journal of Bone and Mineral Research 2: 595–610.
23. Gazzerro E, Gangji V, Canalis E (1998) Bone morphogenetic proteins induce
the expression of noggin, which limits their activity in cultured rat osteoblasts.
J Clin Invest 102: 2106–2114.
24. Haudenschild DR, Palmer SM, Moseley TA, You Z, Reddi AH (2004) Bone
morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in
prostate cancer. Cancer Res 64: 8276–8284.
25. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, et al. (1996) Evidence for a
causal role of parathyroid hormone-related protein in the pathogenesis of human
breast cancer-mediated osteolysis. Journal of Clinical Investigation 98:
1544–1549.
26. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, et al. (1999) TGF-beta
signaling blockade inhibits PTHrP secretion by breast cancer cells and bone
metastases development. Journal of Clinical Investigation 103: 197–206.
27. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, et al. (2001) Multiple
myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone
destruction and promote tumor progression. Proceedings of the National
Academy of Sciences of the United States of America 98: 11581–11586.
28. Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, et al. (2003) Interleukin-
8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the
increased osteolysis of metastatic bone disease. Bone 33: 28–37.
29. Canalis E (2009) Growth factor control of bone mass. J Cell Biochem 108:
769–777.
30. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, et al. (2003) The role of the
Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in
multiple myeloma. N Engl J Med 349: 2483–2494.
31. Clines GA, Mohammad KS, Bao YD, Stephens OW, Suva LJ, et al. (2007)
Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation.
Molecular Endocrinology 21: 486–498.
Role of Noggin in Osteolytic Bone Metastasis
PLoS ONE | www.plosone.org 9 January 2011 | Volume 6 | Issue 1 | e1607832. Oshima T, Abe M, Asano J, Hara T, Kitazoe K, et al. (2005) Myeloma cells
suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood
106: 3160–3165.
33. Taube T, Elomaa I, Blomqvist C, Beneton MNC, Kanis JA (1994)
Histomorphometric Evidence for Osteoclast-Mediated Bone-Resorption in
Metastatic Breast-Cancer. Bone 15: 161–166.
34. Vukmirovic-Popovic S, Colterjohn N, Lhotak S, Duivenvoorden WCM,
Orr FW, et al. (2002) Morphological, histomorphometric, and microstructural
alterations in human bone metastasis from breast carcinoma. Bone 31: 529–535.
35. Kulenkampff HA, Dreyer T, Kersjes W, Delling G (1986) Histomorphometric
Analysis of Osteoclastic Bone-Resorption in Metastatic Bone-Disease from
Various Primary Malignomas. Virchows Archiv a-Pathological Anatomy and
Histopathology 409: 817–828.
36. Parfitt A (1995) Bone remodeling, normal and abnormal: a biological basis for
the understanding of cancer-related bone disease and its treatment. The
Canadian journal of oncology 5: 1–10.
37. Mastro AM, Gay CV, Welch DR, Donahue HJ, Jewell J, et al. (2004) Breast
cancer cells induce osteoblast apoptosis: A possible contributor to bone
degradation. Journal of Cellular Biochemistry 91: 265–276.
38. Mercer RR, Miyasaka C, Mastro AM (2004) Metastatic breast cancer cells
suppress osteoblast adhesion and differentiation. Clinical & Experimental
Metastasis 21: 427–435.
39. Morrissey C, Lai JS, Brown LG, Wang YC, Roudier MP, et al. (2010) The
expression of osteoclastogenesis-associated factors and osteoblast response to
osteolytic prostate cancer cells. Prostate 70: 412–424.
40. Brunet LJ, McMahon JA, McMahon AP, Harland RM (1998) Noggin, cartilage
morphogenesis, and joint formation in the mammalian skeleton. Science 280:
1455–1457.
41. Devlin RD, Du Z, Pereira RC, Kimble RB, Economides AN, et al. (2003)
Skeletal overexpression of noggin results in osteopenia and reduced bone
formation. Endocrinology 144: 1972–1978.
42. Wu XB, Li Y, Schneider A, Yu W, Rajendren G, et al. (2003) Impaired
osteoblastic differentiation, reduced bone formation, and severe osteoporosis in
noggin-overexpressing mice. J Clin Invest 112: 924–934.
43. Barnes J, Anthony CT, Wall N, Steiner MS (1995) Bone morphogenetic protein-
6 expression in normal and malignant prostate. World J Urol 13: 337–343.
44. Hamdy FC, Autzen P, Robinson MC, Horne CH, Neal DE, et al. (1997)
Immunolocalization and messenger RNA expression of bone morphogenetic
protein-6 in human benign and malignant prostatic tissue. Cancer Res 57:
4427–4431.
45. Dai J, Keller J, Zhang J, Lu Y, Yao Z, et al. (2005) Bone morphogenetic protein-
6 promotes osteoblastic prostate cancer bone metastases through a dual
mechanism. Cancer Res 65: 8274–8285.
46. Hall CL, Kang S, MacDougald OA, Keller ET (2006) Role of Wnts in prostate
cancer bone metastases. J Cell Biochem 97: 661–672.
47. Harris SE, Harris MA, Mahy P, Wozney J, Feng JQ, et al. (1994) Expression of
bone morphogenetic protein messenger RNAs by normal rat and human
prostate and prostate cancer cells. Prostate 24: 204–211.
48. Buijs JT, Henriquez NV, van Overveld PG, van der Horst G, ten Dijke P, et al.
(2007) TGF-beta and BMP7 interactions in tumour progression and bone
metastasis. Clin Exp Metastasis 24: 609–617.
49. Buijs JT, Rentsch CA, van der Horst G, van Overveld PG, Wetterwald A, et al.
(2007) BMP7, a putative regulator of epithelial homeostasis in the human
prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo.
Am J Pathol 171: 1047–1057.
50. Neri B, Cecchettin M, Pacini P, Bartalucci S, Gemelli MT, et al. (1989)
Osteocalcin as a biological marker in the therapeutic management of breast
cancer bone metastases. Cancer Invest 7: 551–555.
51. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, et al. (2007) Antibody-based
inhibition of DKK1 suppresses tumor-induced bone resorption and multiple
myeloma growth in vivo. Blood 109: 2106–2111.
52. Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD, Jr., et al.
(2009) Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and
prevents the development of osteolytic bone disease in multiple myeloma. J Bone
Miner Res 24: 425–436.
53. Bu G, Lu W, Liu CC, Selander K, Yoneda T, et al. (2008) Breast cancer-derived
Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression:
implication for breast cancer osteolytic bone metastases. Int J Cancer 123:
1034–1042.
54. Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET (2005) Prostate cancer cells
promote osteoblastic bone metastases through Wnts. Cancer Res 65:
7554–7560.
55. Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, et al. (2007)
Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer
97: 964–970.
56. Hartmann C (2006) A Wnt canon orchestrating osteoblastogenesis. Trends in
Cell Biology 16: 151–158.
57. Dai JL, Hall CL, Escara-Wilke J, Mizokami A, Keller JM, et al. (2008) Prostate
cancer induces bone metastasis through Wnt-induced bone morphogenetic
protein-dependent and independent mechanisms. Cancer Research 68:
5785–5794.
58. Ohazama A, Johnson EB, Ota MS, Choi HY, Porntaveetus T, et al. (2008) Lrp4
modulates extracellular integration of cell signaling pathways in development.
PLoS One 3: e4092.
59. Lintern KB, Guidato S, Rowe A, Saldanha JW, Itasaki N (2009) Character-
ization of Wise Protein and Its Molecular Mechanism to Interact with both Wnt
and BMP Signals. Journal of Biological Chemistry 284: 23159–23168.
60. Chanda D, Isayeva T, Kumar S, Hensel JA, Sawant A, et al. (2009) Therapeutic
Potential of Adult Bone Marrow-Derived Mesenchymal Stem Cells in Prostate
Cancer Bone Metastasis. Clinical Cancer Research 15: 7175–7185.
61. van der Pluijm G, Que I, Sijmons B, Buijs JT, Lowik CWGM, et al. (2005)
Interference with the microenvironmental support impairs the de novo
formation of bone metastases in vivo. Cancer Research 65: 7682–7690.
62. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, et al. (1995)
Bisphosphonate risedronate reduces metastatic human breast cancer burden in
bone in nude mice. Cancer Res 55: 3551–3557.
63. Yaccoby S, Wezernan MJ, Zangari M, Walker R, Cottler-Fox M, et al. (2006)
Inhibitory effects of osteoblasts and increased bone formation on myeloma in
novel culture systems and a myelomatous mouse model. Haematologica-the
Hematology Journal 91: 192–199.
6 4 .F e e l e yB T ,K r e n e kL ,L i uN ,H s uW K ,G a m r a d tS C ,e ta l .( 2 0 0 6 )
Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate
cancer lesions. Bone 38: 154–166.
65. Dougall WC, Chaisson M (2006) The RANK/RANKL/OPG triad in cancer-
induced bone diseases. Cancer and Metastasis Reviews 25: 541–549.
66. Buckle CH, Neville-Webbe HL, Croucher PI, Lawson MA (2010) Targeting
RANK/RANKL in the Treatment of Solid Tumours and Myeloma. Curr
Pharm Des.
Role of Noggin in Osteolytic Bone Metastasis
PLoS ONE | www.plosone.org 10 January 2011 | Volume 6 | Issue 1 | e16078